MX2009006691A - Vacuna de celula tumoral universal para utilizacion terapeutica y profilactica anti-cancerigena. - Google Patents
Vacuna de celula tumoral universal para utilizacion terapeutica y profilactica anti-cancerigena.Info
- Publication number
- MX2009006691A MX2009006691A MX2009006691A MX2009006691A MX2009006691A MX 2009006691 A MX2009006691 A MX 2009006691A MX 2009006691 A MX2009006691 A MX 2009006691A MX 2009006691 A MX2009006691 A MX 2009006691A MX 2009006691 A MX2009006691 A MX 2009006691A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- allogeneic
- prophylactic
- utilization
- endometrium
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229940030325 tumor cell vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000000735 allogeneic effect Effects 0.000 abstract 3
- 206010025323 Lymphomas Diseases 0.000 abstract 2
- 208000009956 adenocarcinoma Diseases 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 210000003679 cervix uteri Anatomy 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 210000004696 endometrium Anatomy 0.000 abstract 2
- 230000000762 glandular Effects 0.000 abstract 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract 2
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 2
- 210000003734 kidney Anatomy 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 201000001441 melanoma Diseases 0.000 abstract 2
- 210000001672 ovary Anatomy 0.000 abstract 2
- 210000000496 pancreas Anatomy 0.000 abstract 2
- 210000002307 prostate Anatomy 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 210000001685 thyroid gland Anatomy 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000006028 immune-suppresssive effect Effects 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención proporciona una composición para estimular una respuesta inmunitaria en un paciente que tiene diferentes tipos de cáncer incluyendo aquellos que tienen adenocarcinoma que comprende una combinación, de células tumorales alogénicas y/o células madre tumorales que se seleccionan sobre las bases de secretar por lo menos un agente inmunosupresor; por ejemplo, TGF-ß, y que están genéticamente modificadas para reducir o inhibir la expresión del al menos un agente inmunosupresor, por ejemplo, TGF-ß, y que colectivamente expresan un espectro de antígenos asociados con el tumor representantes de carcinomas de colón, pecho, pulmón, próstata, páncreas, riñón, endometrio, cerviz, ovario, tiroides y otros tejidos glandulares, así como espinocelular, melanoma, sistema nervioso central y linfomas, y un portador fisiológicamente aceptable. El adenocarcinoma puede ser, por ejemplo, de colón, pecho, pulmón, próstata, páncreas, riñón, endometrio, cerviz, ovario, tiroides u otro tejido glandular, así como espinocelular, melanoma, sistema nervioso central y linfomas. La invención también proporciona una composición que contiene la combinación de células tumorales alogénicas y/o células madre tumorales y una célula alogénica que expresa una citosina o un anticuerpo que inhibe una molécula supresora inmune.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87622206P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/088457 WO2008105978A1 (en) | 2006-12-20 | 2007-12-20 | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006691A true MX2009006691A (es) | 2009-09-09 |
Family
ID=39233098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006691A MX2009006691A (es) | 2006-12-20 | 2007-12-20 | Vacuna de celula tumoral universal para utilizacion terapeutica y profilactica anti-cancerigena. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8293252B2 (es) |
| EP (2) | EP2101812A1 (es) |
| JP (2) | JP2010514697A (es) |
| KR (1) | KR20090107507A (es) |
| AU (1) | AU2007347689B2 (es) |
| BR (1) | BRPI0720689A2 (es) |
| CA (1) | CA2673607A1 (es) |
| EA (1) | EA017613B1 (es) |
| ES (1) | ES2547958T3 (es) |
| HU (1) | HUE027617T2 (es) |
| MX (1) | MX2009006691A (es) |
| NO (1) | NO20092339L (es) |
| NZ (1) | NZ578181A (es) |
| SG (1) | SG192304A1 (es) |
| WO (1) | WO2008105978A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2342334A4 (en) * | 2008-09-29 | 2012-03-14 | Univ Pennsylvania | TARGETED VACCINES ON A TUMOR VASCULAR MARKER |
| CN106434648A (zh) * | 2010-07-19 | 2017-02-22 | F·C·贝内特 | 肌强直性营养障碍蛋白激酶(dmpk)表达的调节 |
| AU2012257377B2 (en) | 2011-05-17 | 2017-09-07 | Hadasit Medical Research Services And Development Ltd. | Allogeneic tumor cell vaccination |
| US20130095575A1 (en) * | 2011-10-03 | 2013-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for Fractionation, Analysis and Collection of Microvesicles From Patient Samples |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| JP7246617B2 (ja) * | 2017-02-01 | 2023-03-28 | アクセルロン ファーマ インコーポレイテッド | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
| WO2021113328A1 (en) * | 2019-12-03 | 2021-06-10 | Neuvogen, Inc. | Tumor cell vaccines |
| CN111351942B (zh) * | 2020-02-25 | 2024-03-26 | 北京尚医康华健康管理有限公司 | 肺癌肿瘤标志物筛选系统及肺癌风险分析系统 |
| AU2021368780A1 (en) * | 2020-11-02 | 2023-06-22 | Neuvogen, Inc. | Tumor cell vaccines |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| US20020006413A1 (en) * | 2000-01-27 | 2002-01-17 | Sobol Robert E. | Genetically engineered tumor cell vaccines |
| AU2001253031A1 (en) * | 2000-03-31 | 2001-10-15 | Novarx | Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| GB0406215D0 (en) * | 2004-03-19 | 2004-04-21 | Procure Therapeutics Ltd | Prostate stem cell |
-
2007
- 2007-12-20 EP EP07873860A patent/EP2101812A1/en not_active Withdrawn
- 2007-12-20 NZ NZ578181A patent/NZ578181A/en not_active IP Right Cessation
- 2007-12-20 ES ES11184308.2T patent/ES2547958T3/es active Active
- 2007-12-20 US US12/520,485 patent/US8293252B2/en not_active Expired - Fee Related
- 2007-12-20 MX MX2009006691A patent/MX2009006691A/es not_active Application Discontinuation
- 2007-12-20 SG SG2012005021A patent/SG192304A1/en unknown
- 2007-12-20 EP EP11184308.2A patent/EP2404614B1/en not_active Not-in-force
- 2007-12-20 BR BRPI0720689-5A2A patent/BRPI0720689A2/pt not_active IP Right Cessation
- 2007-12-20 HU HUE11184308A patent/HUE027617T2/en unknown
- 2007-12-20 KR KR1020097015217A patent/KR20090107507A/ko not_active Application Discontinuation
- 2007-12-20 JP JP2009543236A patent/JP2010514697A/ja not_active Withdrawn
- 2007-12-20 CA CA002673607A patent/CA2673607A1/en not_active Abandoned
- 2007-12-20 WO PCT/US2007/088457 patent/WO2008105978A1/en active Search and Examination
- 2007-12-20 AU AU2007347689A patent/AU2007347689B2/en not_active Ceased
- 2007-12-20 EA EA200970607A patent/EA017613B1/ru not_active IP Right Cessation
-
2009
- 2009-06-18 NO NO20092339A patent/NO20092339L/no not_active Application Discontinuation
-
2012
- 2012-10-23 US US13/658,688 patent/US20130064856A1/en not_active Abandoned
-
2013
- 2013-03-29 JP JP2013071300A patent/JP2013129677A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA200970607A1 (ru) | 2010-04-30 |
| EP2404614B1 (en) | 2015-06-17 |
| NZ578181A (en) | 2012-02-24 |
| AU2007347689A1 (en) | 2008-09-04 |
| AU2007347689A2 (en) | 2009-07-30 |
| ES2547958T3 (es) | 2015-10-09 |
| NO20092339L (no) | 2009-08-25 |
| AU2007347689B2 (en) | 2013-08-15 |
| JP2010514697A (ja) | 2010-05-06 |
| CA2673607A1 (en) | 2008-09-04 |
| SG192304A1 (en) | 2013-08-30 |
| KR20090107507A (ko) | 2009-10-13 |
| EP2404614A1 (en) | 2012-01-11 |
| US20130064856A1 (en) | 2013-03-14 |
| HUE027617T2 (en) | 2016-11-28 |
| EP2101812A1 (en) | 2009-09-23 |
| US20100047289A1 (en) | 2010-02-25 |
| JP2013129677A (ja) | 2013-07-04 |
| WO2008105978A1 (en) | 2008-09-04 |
| EA017613B1 (ru) | 2013-01-30 |
| US8293252B2 (en) | 2012-10-23 |
| BRPI0720689A2 (pt) | 2014-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006691A (es) | Vacuna de celula tumoral universal para utilizacion terapeutica y profilactica anti-cancerigena. | |
| PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
| Sasse et al. | Comparing long-term toxicity and efficacy of combined modality treatment including extended-or involved-field radiotherapy in early-stage Hodgkin's lymphoma | |
| MXPA03001389A (es) | Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu. | |
| TW200616615A (en) | Compounds and methods for the treatment of cancer | |
| MXPA03000527A (es) | Composiciones y metodos para la terapia y diagnostico de cancer ovarico. | |
| MXPA03001634A (es) | Polipeptido tumoral cripto. | |
| JP2010514697A5 (es) | ||
| WO2008033393A3 (en) | Isolation, expansion and uses of tumor stem cells | |
| EP1934246B8 (en) | Matrix metalloproteinase 11 vaccine | |
| EP1272636B8 (en) | A gene differentially expressed in breast and bladder cancer and encoded polypeptides | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| Imai et al. | Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor‐specific CD8+ T cells | |
| CR20120429A (es) | Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello | |
| MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
| Takahashi et al. | Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: immunomodulatory effects of chemotherapy | |
| HK1116186A1 (en) | Azaxanthones and use thereof for treating tumors | |
| MX2021005400A (es) | Terapia del cancer con celulas inmunitarias anti-ptk7. | |
| WO2014145817A3 (en) | Novel therapeutic target for the treatment of cancers and related therapies and methods | |
| WO2006045750A3 (en) | T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use | |
| WO2009032256A3 (en) | Apc activators in combination with a cytokine-secreting cell and methods of use thereof | |
| HK1130693A1 (en) | Tumour vaccine comprising allogeneic or xenogeneic tumour cells | |
| WO2020176461A3 (en) | Methods and compositions for treating neuroendocrine prostate cancer | |
| Kudo-Saito et al. | Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity | |
| WO2004003166A3 (en) | Antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |